More than half of patients treated with tabelecleucel for Epstein-Barr virus-driven post-transplant lymphoproliferative disease responded to therapy, phase 3 study results showed.
Tabelecleucel (Atara Biotherapeutics) is an allogeneic, nongene-edited, Epstein-Barr virus (EBV)-specific T-cell therapy.
The agent is derived from previously untreated peripheral blood mononuclear cells from unrelated donors that are separated, cultured and expanded to produce an IV infusion of T cells that specifically target EBV-infected cells.
A planned interim analysis of the ALLELE trial — presented at